The accumulation of genetic and epigenetic signaling pathway alterations in genes, causing the acquisition of different cancer phenotypes, highlighted a distinct number of oncogenes targeted by mutations, leading to the activation of tumor suppressor pathways, including p53, Rb/INK4/ARF, and Notch in HNSCCs [60]. The gene discussed is CDKN2A; the disease is cancer.